Delivery Order SPE2DB22D3004-SPE2DB24FRG77

Award Date 8/2/24
Potential Completion Date 8/5/24
Potential Value $8.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the supply of XIFAXAN 550 mg tablets to the Defense Logistics Agency (DLA). The contract is a Delivery Order with a Firm Fixed Price of $30,902.72 and an ultimate completion date of July 17, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical...
This federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, is for the delivery of XIFAXAN 550 mg tablets over a period ending on September 23, 2024. The $40,062.50 firm fixed-price delivery order was placed by the Defense Logistics Agency (DLA) Troop Support Medical, a defense agency. The contract does not have a set-aside designation. AmerisourceBergen holds several Indefinite Delivery Contracts (IDCs) with the DLA and other federal agencies, valued up to...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,020.90, is for the delivery of XIFAXAN 550 mg tablets. The award is a delivery order under the company's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which has a potential value of $999,999,999.00 and runs through November 2026. This IDC serves as the primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $9,542.83, is a Delivery Order for the pharmaceutical product XIFAXAN 550 MG TABLET 60S. The contract has an ultimate completion date of January 23, 2025 and is a Firm Fixed Price arrangement. The award is associated with a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds...
This federal contract award is a delivery order worth $11,191.84 issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product, with a completion date of May 22, 2025. The contract is a firm fixed-price arrangement and does not have a set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,315.91 firm fixed-price delivery order is for the supply of XIFAXAN 550 mg tablets. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical. This IDC serves as a primary mechanism for the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The $7,034.95 firm fixed price delivery order is for the supply of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. The award is associated with a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 that Amerisourcebergen Drug...
This federal contract award to Amerisourcebergen Drug Corp is a delivery order with a firm fixed price of $1,213.74 and a completion date of June 3, 2024. The contract was awarded by the Defense Logistics Agency (DLA) for the supply of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. This contract is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical, which serves as a comprehensive vehicle for...
This federal contract award, valued at $11,806.49, was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order contract for the supply of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. The contract has an ultimate completion date of January 9, 2025 and is a firm fixed-price contract. This award is part of a larger Indefinite Delivery Contract (IDC) held by...
This federal contract award, valued at $10,436.12, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XIFAXAN 550 mg tablets, a pharmaceutical product. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves...
  • SPE2DB22D3004
    Indefinite Delivery Contract
  • SPE2DB22D3004-SPE2DB24FRG77
    Delivery Order

This federal contract award, valued at $8,223.22, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of XIFAXAN 550 mg tablets. The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of August 5, 2024. Amerisourcebergen holds several Indefinite Delivery Contracts (IDCs) with the DLA and other federal agencies, valued up to $999,999,999, to provide a wide range of pharmaceutical and medical supplies to support military treatment programs and facilities worldwide, as well as other federal healthcare needs. This specific award does not have a set-aside designation.

Generated 11/1/24, 10:18 AM